INVESTORS INFORMATION
If you are a shareholder of Acticor Biotech, please clic here to access your dedicated area.
You have to identify with a login and password. If you do not have them, you can request the administrator through the provided form at the bottom of next page.
For questions please contact us here.
Acticor Biotech bets on crowdfunding for health and successfully raises its first seed round
Acticor Biotech announced on January 26, 2015, the successful closing of its first capital increase for a total of €590,000. This amount, raised from investors of the crowdfunding platform Anaxago and Business Angels, enables the young Inserm (French National Institute of Health and Medical Research) spin-off to launch the development of its product. The drug candidate ACT-017 is a humanized antibody (Fab) directed against a new target of major interest for the treatment of cerebral stroke, the platelet glycoprotein VI (GPVI).
With two thirds of the capital increase raised with the equity crowdfunding platform Anaxago, Acticor Biotech becomes one of the first companies to successfully raise equity crowd-funds for therapeutic biotechnologies. The level of investors interest in this project demonstrates the strong will of participants to support the development of innovative solutions addressing major public health concerns.
